TXMD (TherapeuticsMD) Cyclically Adjusted Book per Share: $8.46 (As of Mar. 2026)


TXMD TherapeuticsMD Inc TXMD
54 GF Score
Price $2.26
GF Value $2.06
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is TherapeuticsMD Cyclically Adjusted Book per Share?

TherapeuticsMD TXMD +5.12% 54 Cyclically Adjusted Book per Share is $8.46 as of Mar. 2026. GuruFocus rates TXMD with a GF Score™ of 54/100 and a GF Value™ of $2.06 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

TherapeuticsMD's adjusted book value per share for the three months ended in Mar. 2026 was $2.330. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, TherapeuticsMD's average Cyclically Adjusted Book Growth Rate was -26.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -13.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of TherapeuticsMD was 52.70% per year. The lowest was -13.40% per year. And the median was 19.75% per year.

As of today (2026-07-01), TherapeuticsMD's current stock price is $2.26. TherapeuticsMD's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $8.46. TherapeuticsMD's Cyclically Adjusted PB Ratio of today is 0.27.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TherapeuticsMD was 24.93. The lowest was 0.06. And the median was 0.26.


TherapeuticsMD  (NAS:TXMD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

TherapeuticsMD's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.26/8.46
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TherapeuticsMD was 24.93. The lowest was 0.06. And the median was 0.26.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


TherapeuticsMD Cyclically Adjusted Book per Share Related Terms


TherapeuticsMD Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for TherapeuticsMD's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TherapeuticsMD Cyclically Adjusted Book per Share Chart

TherapeuticsMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.57 15.15 13.64 12.11 9.83

TherapeuticsMD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.47 11.02 10.41 9.83 8.46

TXMD vs CPHI, RMTI, AYTU: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Cyclically Adjusted PB Ratio falls into.


TXMD
54GF Score
TherapeuticsMD Inc TXMD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TherapeuticsMD Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TherapeuticsMD's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.33/330.2130*330.2130
=2.330

Current CPI (Mar. 2026) = 330.2130.

TherapeuticsMD Quarterly Data

Book Value per Share CPI Adj_Book
201606 42.557 241.018 58.306
201609 37.221 241.428 50.909
201612 32.407 241.432 44.324
201703 27.778 243.801 37.624
201706 22.933 244.955 30.915
201709 34.531 246.819 46.198
201712 30.009 246.524 40.196
201803 24.770 249.554 32.776
201806 17.880 251.989 23.430
201809 28.381 252.439 37.125
201812 20.279 251.233 26.654
201903 12.581 254.202 16.343
201906 1.678 256.143 2.163
201909 -4.399 256.759 -5.657
201912 1.696 256.974 2.179
202003 -8.320 258.115 -10.644
202006 -17.277 257.797 -22.130
202009 -21.267 260.280 -26.981
202012 -20.684 260.474 -26.222
202103 -1.205 264.877 -1.502
202106 -6.211 271.696 -7.549
202109 -6.750 274.310 -8.126
202112 -10.889 278.802 -12.897
202203 -16.216 287.504 -18.625
202206 -2.942 296.311 -3.279
202209 -5.099 296.808 -5.673
202212 3.700 296.797 4.117
202303 3.354 301.836 3.669
202306 2.950 305.109 3.193
202309 2.653 307.789 2.846
202312 2.540 306.746 2.734
202403 2.486 312.332 2.628
202406 2.399 314.175 2.521
202409 2.349 315.301 2.460
202412 2.373 315.605 2.483
202503 2.310 319.799 2.385
202506 2.358 322.561 2.414
202509 2.371 324.800 2.411
202512 2.322 324.054 2.366
202603 2.330 330.213 2.330

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $8.46 mean?
TherapeuticsMD (TXMD) has a Cyclically Adjusted Book per Share of $8.46 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on TherapeuticsMD and its competitors.
Is TherapeuticsMD's Cyclically Adjusted Book per Share too high?
TherapeuticsMD's current Cyclically Adjusted Book per Share is $8.46. Overall, TherapeuticsMD has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TherapeuticsMD's Cyclically Adjusted Book per Share compare to CPHI and RMTI?
TherapeuticsMD's Cyclically Adjusted Book per Share of $8.46 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on TherapeuticsMD and its competitors. TherapeuticsMD's current Cyclically Adjusted Book per Share is $8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TherapeuticsMD stock overvalued right now?
Based on GuruFocus' analysis, TherapeuticsMD (TXMD) is currently considered Fairly Valued. The stock's GF Value™ is $2.06, compared to a current price of $2.26 — trading 9.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is $8.46. TherapeuticsMD's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For TherapeuticsMD (TXMD), the current Cyclically Adjusted Book per Share is $8.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TherapeuticsMD (TXMD) Overvalued in 2026?

Based on GuruFocus' analysis, TherapeuticsMD stock appears to be overvalued. The current stock price of $2.26 is trading 9.7% above its estimated GF Value™ of $2.06. GuruFocus considers TherapeuticsMD to be Fairly Valued.

Key valuation signals for TXMD:

  • Cyclically Adjusted Book per Share: $8.46
  • GF Value™: $2.06 vs. price of $2.26 (9.7% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the TXMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TherapeuticsMD Business Description

Other Exchanges 29TA:Germany
Address 951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
54GF Score

Get the complete analysis for TXMD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price
$2.06
GF Value